Skip to main content
رجوع
SUPN logo

Supernus Pharmaceuticals, Inc.

جودة البيانات: 100%
SUPN
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 49.25
▲ KWD 1.49 (3.12%)
القيمة السوقية: 2.84B
نطاق اليوم
KWD 47.75 KWD 49.34
نطاق 52 أسبوعًا
KWD 29.16 KWD 59.68
حجم التداول
558,737
متوسط 50 يوم / 200 يوم
KWD 51.14 / KWD 45.13
الإغلاق السابق
KWD 47.76

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (626 نظير)

المقياس السهم وسيط القطاع
P/E -73.6 0.4
P/B 0.0 2.9
ROE % 0.0 3.8
Net Margin % -5.4 3.9
Rev Growth 5Y % 5.5 10.0
D/E 0.0 0.2

السعر المستهدف للمحللين

Hold
KWD 62.000 +25.9%
Low: KWD 55.000 High: KWD 65.000
مكرر الربحية المستقبلي
25.6
ربحية السهم المستقبلية
KWD 1.923
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
870 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 7.010
KWD 6.770 – KWD 7.191
1.4 B 1
FY2029 KWD 6.905
KWD 6.669 – KWD 7.083
1.3 B 1
FY2028 KWD 5.193
KWD 2.334 – KWD 8.053
1.2 B 2

النقاط الرئيسية

Revenue grew 5.53% annually over 5 years — modest growth
Earnings declined -152.19% over the past year
Debt/Equity of 0.03 — conservative balance sheet
Generating 45.99M in free cash flow
PEG of 0.48 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 3.10%

النمو

Revenue Growth (5Y)
5.53%
Revenue (1Y)8.63%
Earnings (1Y)-152.19%
FCF Growth (3Y)-35.49%

الجودة

Return on Equity
-0.01%
ROIC0.00%
Net Margin-5.36%
Op. Margin-5.13%

الأمان

Debt / Equity
0.03
Current Ratio1.90
Interest Coverage0.00

التقييم

P/E Ratio
-73.56
P/B Ratio0.00
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 8.63% Revenue Growth (3Y) 8.79%
Earnings Growth (1Y) -152.19% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 5.53% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 718.95M Net Income (TTM) -38.55M
ROE -0.01% ROA 0.00%
Gross Margin 89.63% Operating Margin -5.13%
Net Margin -5.36% Free Cash Flow (TTM) 45.99M
ROIC 0.00% FCF Growth (3Y) -35.49%
Safety
Debt / Equity 0.03 Current Ratio 1.90
Interest Coverage 0.00 Dividend Yield 0.00%
Valuation
P/E Ratio -73.56 P/B Ratio 0.00
P/S Ratio 3.94 PEG Ratio 0.48
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.84B Enterprise Value -95.25B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 718.95M 661.82M 607.52M 667.24M 579.78M
Net Income -38.55M 73.87M 1.32M 60.71M 53.42M
EPS (Diluted) -0.68 1.32 0.02 1.04 0.98
Gross Profit 644.39M 583.91M 523.74M 580.02M 504.71M
Operating Income -36.86M 81.67M -5.27M 46.12M 86.03M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.45T 1.37B 1.28B 1.70B 1.69B
Total Liabilities 390.93B 332.34M 356.16M 816.30M 873.30M
Shareholders' Equity 1.06T 1.04B 921.52M 886.20M 815.85M
Total Debt 30.37B 34.27M 41.53M 444.76M 427.03M
Cash & Equivalents 128.45B 69.33M 75.05M 93.12M 203.43M
Current Assets 644.18B 686.07M 493.11M 734.15M 601.59M
Current Liabilities 338.17B 292.40M 290.20M 687.96M 315.38M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)
Mar 24, 2026